Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics (Q37431491)

20 August 2017

1 reference

title

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics (English)

1 reference

20 August 2017

Mark S Cragg

1

0 references

Andreas Strasser

object named as

Andreas Strasser

series ordinal

3

0 references

author name string

Claire Harris

series ordinal

2

1 reference

20 August 2017

Clare L Scott

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

3 April 2009

1 reference

20 August 2017

published in

Nature Reviews Cancer

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

321-326

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

20 August 2017

cites work

1 reference

Translation of the Philadelphia chromosome into therapy for CML.

31 March 2020

1 reference

Integration of EGFR inhibitors with radiochemotherapy

31 March 2020

1 reference

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

31 March 2020

1 reference

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

Targeting cancer with small molecule kinase inhibitors

31 March 2020

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

31 March 2020

1 reference

The BCL-2 protein family: opposing activities that mediate cell death

31 March 2020

1 reference

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

31 March 2020

1 reference

Promoting apoptosis as a strategy for cancer drug discovery

31 March 2020

1 reference

Bim and Bad mediate imatinib-induced killing of Bcr/Abl leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

31 March 2020

1 reference

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

31 March 2020

1 reference

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion

31 March 2020

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

31 March 2020

1 reference

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

31 March 2020

1 reference

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

31 March 2020

1 reference

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

31 March 2020

1 reference

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

31 March 2020

1 reference

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

31 March 2020

1 reference

Involvement of BH3-only proteins in hematologic malignancies

31 March 2020

1 reference

BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells

31 March 2020

1 reference

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

31 March 2020

1 reference

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

31 March 2020

1 reference

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

31 March 2020

1 reference

BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

31 March 2020

1 reference

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

31 March 2020

1 reference

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

31 March 2020

1 reference

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

31 March 2020

1 reference

BCL-2 family antagonists for cancer therapy

31 March 2020

1 reference

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

31 March 2020

1 reference

Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models

31 March 2020

1 reference

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

31 March 2020

1 reference

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

31 March 2020

1 reference

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

31 March 2020

1 reference

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

31 March 2020

1 reference

Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

31 March 2020

1 reference

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

31 March 2020

1 reference

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

31 March 2020

1 reference

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

31 March 2020

1 reference

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

31 March 2020

1 reference

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

31 March 2020

1 reference

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

31 March 2020

1 reference

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

31 March 2020

1 reference

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains

31 March 2020

1 reference

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

31 March 2020

1 reference

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

31 March 2020

1 reference

ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2615

1 reference

Dimensions Publication ID

20 August 2017

1023532012

0 references

Fatcat ID

release_oiyqunpgijdrplpwyppbraxkou

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oiyqunpgijdrplpwyppbraxkou

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference